Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-13

yes
as we now on the cusp of entering phase 11
i see this replicating the path of neu
except with multiple times potential revenue prospects, as a result of much deeper need in patient population with added on wider applications across medical needs
latest broker reports for neu anticipate fair value price target of around $10
with similar amount of shares on issue i cant see why recce couldnt indeed exceed such value expectations
given other similar precedents seen recently on little researched emerging biotechs a forecast valuation along those lines could clearly emerge
neu with limited applications was priced around a dollar a year or so ago now what 5.78 with targets of $10
recce seems a really good investment to me at this sub 1$ level with little downside
if as expected now phase 1 tox human trials wrap up by end august and phase 11 schedules announced accordingly
i think we will start to see a substantial gathering of interest and subsequent rerating
have a peek at nsu
just say later i told ya so !
thanks for reading